NAGE
Niagen Bioscience Inc
$3.66
-0.13
(-3.43%)
Mkt Cap
291.50M
Volume
720,142
52W Range
3.57-14.69
Sector
Healthcare
Beta
2.17
EPS (TTM)
0.23
P/E Ratio
15.62
Revenue (TTM)
130.42M
Rev Growth (5Y)
+16.9%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$8.67
Undervalued · Strong
57.8% below fair value
AlphaQuality · Grade · Gated
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
Company Description
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.42M | 99.60M | 83.57M | 72.05M | 67.45M | 59.26M | 46.29M | 31.56M | 21.20M | 21.66M | 17.88M | 15.31M |
| Net Income | 17.38M | 8.55M | (4.94M) | (16.54M) | (27.13M) | (19.93M) | (32.15M) | (33.32M) | (11.38M) | (2.93M) | (2.77M) | (5.39M) |
| EPS | 0.22 | 0.10 | -0.07 | -0.24 | -0.40 | -0.33 | -0.56 | -0.61 | -0.26 | -0.08 | -0.08 | -0.15 |
| Free Cash Flow | 13.14M | 11.95M | 6.97M | (15.43M) | (24.57M) | (10.74M) | (21.19M) | (22.36M) | (11.15M) | (4.66M) | N/A | N/A |
| FCF / Share | 0.17 | 0.14 | 0.10 | -0.22 | -0.37 | -0.18 | -0.37 | -0.41 | -0.25 | -0.12 | N/A | N/A |
| Operating CF | 13.44M | 12.11M | 7.12M | (15.10M) | (24.16M) | (10.60M) | (20.44M) | (20.91M) | (9.80M) | (2.94M) | N/A | N/A |
| Total Assets | 106.41M | 68.28M | 54.96M | 54.06M | 57.84M | 38.36M | 40.25M | 42.23M | 62.72M | 19.75M | N/A | N/A |
| Total Debt | 2.82M | 2.65M | 3.28M | 4.26M | 4.70M | 1.64M | 1.72M | 310,000 | 506,000 | 599,050 | N/A | N/A |
| Cash & Equiv | 64.79M | 44.51M | 27.17M | 20.29M | 28.02M | 16.50M | 18.61M | 22.42M | 45.39M | 1.64M | N/A | N/A |
| Book Value | 76.53M | 46.09M | 28.46M | 28.67M | 31.73M | 16.42M | 20.45M | 27.18M | 53.83M | 9.97M | N/A | N/A |
| Return on Equity | 0.23 | 0.19 | -0.17 | -0.58 | -0.86 | -1.21 | -1.57 | -1.23 | -0.21 | -0.29 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.47M | 33.84M | 33.99M | 31.12M | 30.48M | 29.12M | 25.58M | 22.74M | 22.15M | 21.20M | 19.50M | 20.32M |
| Net Income | 6.32M | 4.13M | 4.58M | 3.61M | 5.06M | 7.18M | 1.88M | (15,000) | (492,000) | 114,000 | (959,000) | (2.19M) |
| EPS | 0.08 | 0.05 | 0.06 | 0.05 | 0.07 | 0.09 | 0.02 | -0.00 | -0.01 | 0.00 | -0.01 | -0.03 |
| Free Cash Flow | (1.25M) | 523,000 | 3.67M | 1.11M | 7.85M | 8.51M | 3.45M | (276,000) | 254,000 | 628,000 | 370,000 | 3.27M |
| FCF / Share | -0.02 | 0.01 | 0.04 | 0.01 | 0.10 | 0.11 | 0.04 | -0.00 | 0.00 | 0.01 | 0.00 | 0.04 |
| Operating CF | (1.19M) | 624,000 | 3.69M | 1.25M | 7.88M | 8.58M | 3.50M | (264,000) | 295,000 | 649,000 | 396,000 | 3.28M |
| Total Assets | 114.33M | 106.41M | 98.14M | 91.53M | 81.34M | 68.28M | 56.52M | 54.03M | 54.08M | 54.96M | 53.48M | 53.17M |
| Total Debt | 2.58M | 2.82M | 3.06M | 3.29M | 3.52M | 2.65M | 2.90M | 3.12M | 3.23M | 3.28M | 3.79M | 3.94M |
| Cash & Equiv | 66.55M | 64.79M | 64.14M | 60.32M | 55.46M | 44.51M | 32.25M | 27.73M | 27.41M | 27.17M | 26.62M | 26.25M |
| Book Value | 82.33M | 76.53M | 70.68M | 64.19M | 55.34M | 46.09M | 34.37M | 30.72M | 28.95M | 28.46M | 27.31M | 27.15M |
| Return on Equity | 0.08 | 0.05 | 0.06 | 0.06 | 0.09 | 0.16 | 0.05 | -0.00 | -0.02 | 0.00 | -0.04 | -0.08 |
NAGE News
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy
Niagen: High-Quality Growth At A Fair Price
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®